Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HCP1803 in Essential Hypertension
NCT05362110Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlodipine, losartan and chlorthalidone in essential hypertension (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change from baseline in sitting systolic blood pressure at 8 weeks. Started May 2022; status: completed.
02
Drugs
amlodipinelosartanchlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05362110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362110.